Checkpoint inhibitor (CPI) therapy has significantly improved overall survival for metastatic melanoma, and is now approved for use in the adjuvant setting. Modulating the immune system is recognized to cause cutaneous immune-related adverse events (irAEs). We conducted a retrospective observational cohort study of adult patients with melanoma at our tertiary referral centre, who received CPI therapy from 2006 to March 2018. This is the single largest study of cutaneous irAEs occurring on CPI therapy in patients with melanoma to date and encompasses 12 years. The results showed that cutaneous toxicity occurs in 24% of patients but is generally manageable, with < 5% patients discontinuing treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14469DOI Listing

Publication Analysis

Top Keywords

patients melanoma
12
cpi therapy
12
checkpoint inhibitor
8
cutaneous
4
cutaneous toxicities
4
patients
4
toxicities patients
4
melanoma
4
melanoma receiving
4
receiving checkpoint
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!